Business · Companies · 12 hrs ago
Cimed invests R$80 million in South Korean-inspired skincare brand
Cimed, a major maker of generic medicines in Brazil, has launched Mili, a skincare brand developed with South Korean laboratory GDK Cosmetics.
The company invested R$80 million to create seven products, including face masks and creams.
The launch expands Cimed’s range beyond medicines as it seeks growth in beauty and personal care.
South Korean cosmetics imports to Brazil reached US$54.3 million in 2025, up 951% from a year earlier.
Cimed plans to expand Mili to between 60 and 100 products over time, with many expected to cost R$100 to R$200.
It is counting on its distribution network, which reaches more than 90,000 sales points and 98% of pharmacies in Brazil, to help sell the products.
Cimed invested R$ 80 million to develop Mili, a South Korean-inspired skincare brand created with laboratory GDK Cosmetics.
The line launches in Brazil with seven products, including facial masks and creams for skin rejuvenation and care.
The launch expands Cimed’s Milimetric portfolio, which focuses on injectable aesthetic procedures.
Cimed plans to develop a future portfolio of 60 to 100 Mili products, many priced between R$ 100 and R$ 200.
The company is drawing on its distribution network of 26 centers and more than 90,000 points of sale.
- Who
- Cimed, in partnership with GDK Cosmetics, developed the Mili skincare brand.
- What
- Cimed invested R$ 80 million in the brand’s development. Its first line has seven skincare products.
- When
- The brand was announced in October 2026.
- Where
- The products are launching in Brazil.
- Why
- Cimed is expanding into skincare and other non-medicine categories to grow its business and compete with multinational consumer-goods companies.
This story does not have two clearly opposing sides.
Cimed announced a similar project, which later changed in concept and name.
Cimed made 130 launches in the beauty and personal-care category.
Cimed announced Mili, developed with GDK Cosmetics, and brought the seven-product line to the Brazilian market.
- Investment
- R$ 80 million
- Initial range
- Seven products
- Planned portfolio
- 60 to 100 products
- Price range
- R$ 100 to R$ 200 for many planned products
- Distribution network
- 26 centers and more than 90,000 points of sale
- Brazilian pharmacy presence
- 98% of pharmacies
What people are saying
Mili é a marca-mãe. Depois, a gente vai brincando com os princípios ativos. São máscaras, cremes faciais, cremes antirrugas e olheiras, e assim vai.
A nossa janela de crescimento é no ‘não medicamento’. É onde a gente vai acelerar a nossa empresa para virar uma empresa de consumo, criando novas categorias.
Isso está começando a crescer no Brasil. Nós devemos ter uma presença mais forte de marcas e de tecnologia sul-coreana, principalmente em skincare, e acho que a Cimed entra nisso com capacidade de distribuição para fazer uma grande escala.
Sources
Related news
Hyundai reveals larger Bayon SUV, planned for Brazilian production in 2027
CSN agrees to sell German steel plant for €550 million
São Paulo high-end office demand doubles historical annual average
Low fees are key to making small pension savings work in Brazil
Mega-Sena draws numbers for estimated R$112 million prize
R$112 million Mega-Sena prize could earn up to R$13.8 million in a year
Santander approves R$1.5 billion in payments to shareholders
Quina contest 7139 draws numbers for a R$30 million prize
Lotomania draws 20 numbers in contest with estimated R$10.3 million prize
Vammo reaches 10 million battery swaps and says it is profitable
Real estate consortium sales in Brazil rise 39.9% in first eight months of 2026
